| Authors: |
Kristeleit R; University College London Cancer Institute, London, UK. rebecca.kristeleit@gstt.nhs.uk.; School of Cancer and Pharmaceutical Sciences, King's College London, London, UK. rebecca.kristeleit@gstt.nhs.uk.; Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK. rebecca.kristeleit@gstt.nhs.uk., Leary A; Gustave Roussy, Villejuif, France., Oaknin A; Gynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitario Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Redondo A; Medical Oncology Department, La Paz University Hospital-IdiPAZ, Madrid, Spain., George A; The Institute of Cancer Research, London, UK.; Royal Marsden NHS Foundation Trust, London, UK., Chui S; Product Development Oncology, Genentech Inc., South San Francisco, CA, USA., Seiller A; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Liste-Hermoso M; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Willis J; Product Development Safety, Roche Products Ltd, Welwyn Garden City, UK., Shemesh CS; Clinical Pharmacology Oncology, Genentech Inc, South San Francisco, CA, USA., Xiao J; Clovis Oncology, San Francisco, CA, USA., Lin KK; Clovis Oncology, San Francisco, CA, USA., Molinero L; Translational Medicine, Genentech Inc., South San Francisco, CA, USA., Guan Y; Translational Medicine, Genentech Inc., South San Francisco, CA, USA., Ray-Coquard I; Centre Leon Bérard, HESPER laboratory EA 7425, Université Claude Bernard Lyon Est, Lyon, France., Mileshkin L; Department of Medical Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, VIC, Australia. |
